Table 2.
Characteristics of children started on antiretroviral treatment (n = 315)
| Age at starta | 7.2 (4.5 – 10.4) |
| < 3 yearsb | 38 (12%) |
| 3 – 4.9 yearsb | 51 (16%) |
| 5 – 14.9 yearsb | 226 (72%) |
| Sex (male/female)b | 157/158 (50/50%) |
| Clinical WHO-stageqb | |
| WHO stage I | 43 (13.7%) |
| WHO stage II | 145 (46.0%) |
| WHO stage III | 115 (36.5%) |
| WHO stage IV | 12 (3.8%) |
| Weight for age (Z-score) (n = 293)a | -1.9 (-3.0;-0.9) |
| Baseline CD4 count % (n = 282)a | 14 (9–18) |
| < 15%b | 158 (56.0%) |
| 15–25%b | 118 (41.8%) |
| > 25%b | 6 (2.1%) |
| Baseline absolute CD4 counts (n= 302)a | 345 (229–572) |
| Baseline hemoglobin (mg/dl)(n = 268)a | 11.0 (10.3–11.8) |
| ART regimenb | |
| d4T/3TC/NVP | 281 (89.2%) |
| d4T/3TC/EFV | 6 (1.9%) |
| AZT/3TC/NVP | 19 (6.0%) |
| AZT/3TC/EFV | 9 (2.9%) |
| Time on ART (years)c | 2.0 (1.2–2.6) |
| Total patient years of follow-up | 598 |
| On tablets (FDC) | 577 |
| On syrup | 21 |
| < 1 year vs. ≥ 1 yearb | 59 (19 %) vs 256 (81 %) |
a Values are expressed as median (interquartile range)
b Values are expressed as n (%)
c As of June 30/2007 (closing date of dataset)
WHO: world health organization; ART: antiretroviral treatment; d4T: stavudine; 3TC: lamivudine; NVP: nevirapine; EFV: efavirenz; AZT: zidovudine; FDC: fixed-dose combination